Detailed Information on Publication Record
2013
Children and adolescents with follicular lymphoma have an excellent prognosis with either limited chemotherapy or with a "watch and wait" strategy after complete resection
ATTARBASCHI, Andishe, Auke BEISHUIZEN, Georg MANN, Angelo ROSOLEN, Tetsuya MORI et. al.Basic information
Original name
Children and adolescents with follicular lymphoma have an excellent prognosis with either limited chemotherapy or with a "watch and wait" strategy after complete resection
Authors
ATTARBASCHI, Andishe (40 Austria), Auke BEISHUIZEN (528 Netherlands), Georg MANN (40 Austria), Angelo ROSOLEN (380 Italy), Tetsuya MORI (392 Japan), Anne UYTTEBROECK (56 Belgium), Felix NIGGLI (756 Switzerland), Monika CSOKA (348 Hungary), Zdenka KŘENOVÁ (203 Czech Republic, guarantor, belonging to the institution), Karin MELLGREN (752 Sweden), Edita KABICKOVA (203 Czech Republic), Alan KS CHIANG (344 Hong Kong), Alfred REITER (276 Germany), Denise WILLIAMS (826 United Kingdom of Great Britain and Northern Ireland) and Birgit BURKHARDT (276 Germany)
Edition
Annals of hematology, Berlin, Springer Verlag, 2013, 0939-5555
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30200 3.2 Clinical medicine
Country of publisher
Germany
Confidentiality degree
není předmětem státního či obchodního tajemství
Impact factor
Impact factor: 2.396
RIV identification code
RIV/00216224:14110/13:00068306
Organization unit
Faculty of Medicine
UT WoS
000325357600012
Keywords in English
"Watch and wait"; Complete resection; Follicular lymphoma; Outcome
Tags
International impact, Reviewed
Změněno: 18/12/2013 15:34, Soňa Böhmová
Abstract
V originále
Data on clinical features and outcome in pediatric follicular lymphoma (pFL) are scarce. The aim of this retrospective study including 13 EICNHL and/or i-BFM study group members was to assess clinical characteristics and course in a series of 63 pFL patients. pFL was found to be associated with male gender (3:1), older age (72 % >/- 10 years old), low serum LDH levels (<500 U/l in 75 %), grade 3 histology (in 88 %), and limited disease (87 % stage I/II disease), mostly involving the peripheral lymph nodes. Forty-four out of sixty-three patients received any polychemotherapy and 1/63 rituximab only, while 17/63 underwent a "watch and wait" strategy. Of 36 stage I patients, 30 had complete resections. Only one patient relapsed; 2-year event-free survival and overall survival were 94 +/- 5 and 100 %, respectively, after a median follow-up of 2.2 years. Conclusively, treatment outcome in pFL seems to be excellent with risk-adapted chemotherapy or after complete resection and an observational strategy only.